KR20130137696A - 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도 - Google Patents

테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도 Download PDF

Info

Publication number
KR20130137696A
KR20130137696A KR1020137028763A KR20137028763A KR20130137696A KR 20130137696 A KR20130137696 A KR 20130137696A KR 1020137028763 A KR1020137028763 A KR 1020137028763A KR 20137028763 A KR20137028763 A KR 20137028763A KR 20130137696 A KR20130137696 A KR 20130137696A
Authority
KR
South Korea
Prior art keywords
tetracycline
inflammatory
calcium
tetracyclines
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020137028763A
Other languages
English (en)
Korean (ko)
Inventor
피오트르 촘진스키
Original Assignee
몰레큘러 리서치 센터, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 몰레큘러 리서치 센터, 인크. filed Critical 몰레큘러 리서치 센터, 인크.
Publication of KR20130137696A publication Critical patent/KR20130137696A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
KR1020137028763A 2007-03-23 2008-03-20 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도 Abandoned KR20130137696A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89656407P 2007-03-23 2007-03-23
US60/896,564 2007-03-23
PCT/US2008/057646 WO2008118744A1 (en) 2007-03-23 2008-03-20 Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097021550A Division KR20090122994A (ko) 2007-03-23 2008-03-20 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도

Publications (1)

Publication Number Publication Date
KR20130137696A true KR20130137696A (ko) 2013-12-17

Family

ID=39651298

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137028763A Abandoned KR20130137696A (ko) 2007-03-23 2008-03-20 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도
KR1020097021550A Ceased KR20090122994A (ko) 2007-03-23 2008-03-20 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097021550A Ceased KR20090122994A (ko) 2007-03-23 2008-03-20 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도

Country Status (9)

Country Link
US (1) US20080233206A1 (https=)
EP (1) EP2125018A1 (https=)
JP (1) JP5395052B2 (https=)
KR (2) KR20130137696A (https=)
CN (2) CN102688492A (https=)
AP (1) AP2657A (https=)
AU (1) AU2008231033B2 (https=)
EA (1) EA016206B1 (https=)
WO (1) WO2008118744A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261143B2 (en) 2003-07-25 2009-11-05 Allergan Pharmaceuticals International Limited A doxycycline metal complex in a solid dosage form
AU2006206359B2 (en) * 2005-01-21 2011-03-31 Allergan Pharmaceuticals International Limited A tetracycline metal complex in a solid dosage form
PT2568987T (pt) * 2010-05-12 2017-02-03 Rempex Pharmaceuticals Inc Composições de tetraciclina
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
CN103536607A (zh) * 2012-07-10 2014-01-29 邵金辉 土霉素，普罗帕酮和安乃近的抗肿瘤作用
PT106679B (pt) * 2012-11-27 2015-03-25 Hovione Farmaciencia Sa Formulações tópicas de tetraciclinas, sua preparação e usos
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
ITMI20132066A1 (it) * 2013-12-11 2015-06-12 Farmatron Ltd Sistemi terapeutici a rilascio modificato per la somministrazione orale di mentolo nel trattamento delle malattie intestinali
WO2015153864A2 (en) * 2014-04-02 2015-10-08 Hopkins Patricia T Methods for treating inflammatory conditions
CN103933539B (zh) * 2014-04-16 2017-01-11 西北农林科技大学 一种含有四环素的药物组合物及其应用
MX2017012062A (es) 2015-03-23 2018-06-18 Biopharmx Inc Composicion farmaceutica de tetraciclina para uso dermatologico.
CN105998037A (zh) * 2016-06-16 2016-10-12 汕头大学 多西环素在制备治疗或预防衰老性疾病的药物中的用途
CO2017001953A1 (es) * 2017-02-27 2018-08-31 Corporacion Univ Lasallista Método de encapsulación de tetraciclinas
MY203238A (en) * 2018-10-29 2024-06-19 Fraunhofer Ges Zur Frderung Der Angewandten Forschung E V Tetracycline complexes with sustained activity
CN110169973A (zh) * 2019-06-11 2019-08-27 贾树森 一种用于颈椎康复的外用药物组合物
CN111870607A (zh) * 2020-07-09 2020-11-03 温州医科大学 盐酸米诺环素作为制备治疗自身免疫性葡萄膜炎药物的应用及其治疗方法
KR102855121B1 (ko) * 2021-12-17 2025-09-04 주식회사 케이씨앤씨 클로르테트라사이클린을 포함하는 고양이 전염성 복막염 치료용 조성물
CN116655491B (zh) * 2023-05-12 2025-01-28 常州大学 一种多功能抗菌纳米材料TCFNPs及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2736725A (en) * 1954-03-11 1956-02-28 American Cyanamid Co Complexes of tetracycline antibiotics and preparation of same
US2766124A (en) * 1954-05-25 1956-10-09 American Cyanamid Co Antibiotic-containing ice composition
US2806789A (en) * 1954-09-10 1957-09-17 American Cyanamid Co Enhancement of therapeutic efficacy of antibiotics
GB901209A (en) * 1957-10-23 1962-07-18 Pfizer & Co C 6-deoxytetracyclines and compositions containing same
GB901107A (en) * 1959-06-29 1962-07-11 Pfizer Therapeutic composition and method of preparing same
GB894619A (en) * 1959-09-11 1962-04-26 Pfizer & Co C Stabilized liquid preparations comprising tetracycline antibiotics
FR1430859A (https=) * 1960-05-23 1966-05-25
US3275513A (en) * 1963-05-29 1966-09-27 American Cyanamid Co Stable calcium tetracycline compositions
US4061676A (en) * 1970-07-03 1977-12-06 Ivan Villax Recovery of doxycycline and products thereof
US3957980A (en) * 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
US4060605A (en) * 1973-09-28 1977-11-29 Ankerfarm, S.P.A. Water-soluble derivative of 6-deoxy-tetracyclines
DK153784C (da) * 1973-09-28 1989-01-23 Pfizer Analogifremgangsmaade til fremstilling af 2-n-(methioninomethyl)doxycyclin eller salte deraf
US4150111A (en) * 1974-05-28 1979-04-17 Allister Warren Enteric coated magnesium chloride
JPS51107134A (en) * 1975-03-17 1976-09-22 Asahi Optical Co Ltd Shotenmenkenshutsusochi
US4081527A (en) * 1976-12-07 1978-03-28 Pfizer Inc. Chlortetracycline compositions
US4126680A (en) * 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
US4837030A (en) * 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
EP0327295A3 (en) * 1988-02-01 1989-09-06 F.H. FAULDING & CO. LTD. Tetracycline dosage form
US5250442A (en) * 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
US5538954A (en) * 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5614206A (en) * 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
DE69627855T2 (de) * 1995-06-13 2004-03-11 Nippon Meat Packers, Inc. Orales mittel gegen rheumatische arthritis und funktionelles nahrungsmittel
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5968896A (en) * 1998-01-16 1999-10-19 Beth Israel Deaconess Medical Center Nutritional supplement for preoperative feeding
CA2360938C (en) * 1999-02-02 2008-01-08 Warren Oliver Haggard Controlled release composite
US6765000B2 (en) * 1999-03-17 2004-07-20 Bonner Jr Ernest L Treatment for reactive arthritis or bursitis
US7884090B2 (en) * 1999-03-17 2011-02-08 Ernest L. Bonner, Jr. Compositions and methods for the treatment of arthritis
US6946118B1 (en) * 1999-09-14 2005-09-20 Orapharma, Inc. Formulations for treating or preventing mucositis
US6638532B2 (en) * 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6887492B2 (en) * 2000-12-14 2005-05-03 Leiner Health Services Corp. Magnesium plus interactive agent delivery
US7211267B2 (en) * 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
EP1383508B1 (en) * 2001-04-05 2006-06-21 Collagenex Pharmaceuticals, Inc. Doxycycline for the treatment of acne
CA2446356C (en) * 2001-05-09 2012-07-10 The Regents Of The University Of Michigan Use of compositions for treating rosacea
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
US7122578B2 (en) * 2001-09-11 2006-10-17 Alain Martin Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration
NO315915B1 (no) * 2002-02-25 2003-11-10 Sintef Elektronikk Og Kybernet Fj¶rvekt
JP2005533766A (ja) * 2002-05-20 2005-11-10 コッラジェネックス ファーマシューチカルス インコーポレイテッド アレルギー反応の治療方法
AU2004261143B2 (en) * 2003-07-25 2009-11-05 Allergan Pharmaceuticals International Limited A doxycycline metal complex in a solid dosage form
EP2033950A1 (en) * 2004-10-25 2009-03-11 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
AU2006206359B2 (en) * 2005-01-21 2011-03-31 Allergan Pharmaceuticals International Limited A tetracycline metal complex in a solid dosage form
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne

Also Published As

Publication number Publication date
AP2657A (en) 2013-05-07
AU2008231033A1 (en) 2008-10-02
AP2009004979A0 (en) 2009-10-31
US20080233206A1 (en) 2008-09-25
KR20090122994A (ko) 2009-12-01
EA016206B1 (ru) 2012-03-30
CN102688492A (zh) 2012-09-26
JP2010522240A (ja) 2010-07-01
WO2008118744A1 (en) 2008-10-02
AU2008231033B2 (en) 2012-08-30
CN101678108A (zh) 2010-03-24
EA200901289A1 (ru) 2010-02-26
EP2125018A1 (en) 2009-12-02
JP5395052B2 (ja) 2014-01-22

Similar Documents

Publication Publication Date Title
KR20130137696A (ko) 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도
CN101084944B (zh) 预防或治疗泌尿系统感染的组合物
US20040162269A1 (en) Composition and method of treating arthritis
JP3806427B2 (ja) 新規鎮痛剤
HRP930755A2 (en) Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
JP5769308B2 (ja) 貧血又はｈ．ピロリ感染に用いる単（鉄ヒドロキシピロン）及び組み合わせ（鉄ヒドロキシピロン及び胃腸炎抑止剤）組成物
KR102351422B1 (ko) 철 트리말톨의 복용량 양생법
HU210330B (en) Process for production of preparations containing n-(4-chlorophenyl)-n"-cyano-n'-(6-cyano-3,4-dyhidro-3-hydroxy-2,2-dimethyl-2h-1 benzopyran-4-yl)-guanidine prophylaxis and/or treatment of gastrointestinal ulcer
Majewski A current opinion on the safety and efficacy of doxycycline including parenteral administration–A review
JP5416327B2 (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
RU2541092C2 (ru) Бисглицинат-хелат железа для использования в пероральном лечении анемии у пациентов с целиакией
ES2694506T3 (es) Administración de ibuprofeno por vía intravenosa
CA2476939A1 (en) Pharmaceutical combinations of cox-2 inhibitors and opiates
JPH06503806A (ja) 胃腸疾病を処置するための５―ジフルオロメトキシ―２―［（３，４―ジメトキシ―２―ピリジル）メチルスルフィニル］ベンズイミダゾール及び抗ヘリコバクター剤含有医薬組成物
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤
KR20010024050A (ko) 항균제
Chomczynski et al. Compositions and methods for anti-inflammatory treatments
Gofur et al. Drug choice to lowering risk contiguity with Morbus Hansen disease: A review article
AU2012230089B2 (en) Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy
HRP20030382A2 (en) A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
JP4614638B2 (ja) 鎮痛剤組成物
CA2565084C (en) Use of sulglicotide for the treatement of mucositis
JP4384435B2 (ja) くしゃみ抑制組成物
JP2008247789A (ja) クローン病に伴う腸管狭窄の進展抑制用医薬組成物
AU2012276476A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20131030

Application number text: 1020097021550

Filing date: 20091015

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140121

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20141023

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee